EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathogen‐Centric Activation of an Azoreductase‐Responsive Antibody‐Antibiotic Conjugate for the Targeted Eradication of MRSA

Qi Cheng, Lianqi Liu, Chenghua Liu, Fei Xie, Jingwen Dong, Xiaoyu Qin, Shunxiang Huang, Xian Li, Xingyuan Kou, Hongbin Deng, Jiannan Feng, Wu Zhong iD und 2 weitere

Advanced Science · 2026

DOI: 10.1002/advs.75541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Qi Cheng und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Nitroreductases, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐antibiotic conjugates (AACs) provide a transformative platform for eradicating intracellular methicillin‐resistant Staphylococcus aureus (MRSA). However, current AACs largely follow antibody‐drug conjugates (ADCs) design principles and rely on host‐lysosomal proteases for activation, rendering them ineffective against extracellular (planktonic) bacteria. Furthermore, we demonstrate that high bacterial burden induces host‐lysosomal dysfunction, fundamentally compromising the efficacy of host‐dependent AACs against intracellular reservoirs. To address these limitations, we developed a pathogen‐centric AAC (AZO‐AAC) featuring an azobenzene‐based linker that is triggered by bacterial‐secreted azoreductase. This strategy shifts the activation mechanism from host‐cell machinery to the pathogen itself, enabling antibiotic release independent of host‐cell integrity. Surprisingly, our designed AZO‐AAC achieves nanomolar‐scale eradication of both planktonic and intracellular MRSA, reaching levels below the limit of detection in scenarios where traditional AACs fail. In murine models of peritonitis and septicemia, a single dose (60 mg/kg) of AZO‐AAC resulted in a six‐log reduction in bacterial burden and the preservation of normal tissue architecture. By decoupling activation from host‐cell status, this pathogen‐responsive platform provides a robust strategy for the targeted elimination of complex, multi‐niche MRSA infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusNitroreductasesAnti-Bacterial AgentsStaphylococcal InfectionsNADH, NADPH OxidoreductasesImmunoconjugatesAnimalsMiceDisease Models, AnimalHumans

Stichwörter der Autor:innen

MRSAacute infectionantibody‐antibiotic conjugatesazoreductasebacterial enzymeperitonitissepticemia

Substanzen

azoreductaseNitroreductasesAnti-Bacterial AgentsNADH, NADPH OxidoreductasesImmunoconjugates

Autor:innen und Institutionen

  • School of Pharmacy, Qingdao University, Qingdao, China.
  • Academy of Military Medical Sciences, Beijing, China.
  • National Engineering Research Center for the Emergency Drug, Beijing, China.
  • School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Wu Zhong, Xinbo Zhou

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program

Zitieren

APA

Cheng, Q., Liu, L., Liu, C., Xie, F., Dong, J., Qin, X., Huang, S., Li, X., Kou, X., Deng, H., Feng, J., Zhong, W., Xiao, D., & Zhou, X. (2026). Pathogen‐Centric Activation of an Azoreductase‐Responsive Antibody‐Antibiotic Conjugate for the Targeted Eradication of MRSA. Advanced Science. https://doi.org/10.1002/advs.75541

Vancouver

Cheng Q, Liu L, Liu C, Xie F, Dong J, Qin X, et al. Pathogen‐Centric Activation of an Azoreductase‐Responsive Antibody‐Antibiotic Conjugate for the Targeted Eradication of MRSA. Advanced Science. 2026. doi:10.1002/advs.75541

BibTeX
@article{Cheng2026,
  author = {Cheng, Qi and Liu, Lianqi and Liu, Chenghua and Xie, Fei and Dong, Jingwen and Qin, Xiaoyu and Huang, Shunxiang and Li, Xian and Kou, Xingyuan and Deng, Hongbin and Feng, Jiannan and Zhong, Wu and Xiao, Dian and Zhou, Xinbo},
  title = {Pathogen‐Centric Activation of an Azoreductase‐Responsive Antibody‐Antibiotic Conjugate for the Targeted Eradication of MRSA},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.75541}
}
Kostenlos starten →